Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Kidney Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 36Nivolumab 16Cyclophosphamide 12atezolizumab 8Docetaxel 8Magnetic Resonance Spectroscopy 7Paclitaxel 6Everolimus 6spartalizumab 5fludarabine 5durvalumab 5Specimen Handling 5Ipilimumab 5cabozantinib 4avelumab 4Trastuzumab 4Radiotherapy 4Radiosurgery 4Oxaliplatin 4Leucovorin 4temsirolimus 3pazopanib 3aldesleukin 3Taxes 3Sunitinib 3Psychiatric Rehabilitation 3Interleukin-2 3Immune Checkpoint Inhibitors 3Gemcitabine 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × ciforadenant × Breast × Clear all
NCT03454451 2023-12-21

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Corvus Pharmaceuticals, Inc.

Phase 1 Completed
117 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡